Diabetes Introduction Treatments Complications Statistics Clinical Trials
NDEP Awareness and Prevention Series Resources Order About NDIC Informacion en Espanol
dots
A to Z list of Diabetes Topics and Titles Easy-to-Read Publications Spanish-language Publications Awareness and Prevention Series
Email to a friend  Email to a friend icon
Print this page    Print this page icon
 Home : Clinical Trials, Guidelines, and Reports : Diabetes Control and Complications Trial : Diabetes Control and Complications Trial (DCCT)
 

Diabetes Control and Complications Trial (DCCT)

Click here to start slide show

Table of Contents

  1. Diabetes Control and Complications Trial (DCCT)
  2. Long-Term Complications of IDDM
  3. Study Questions
  4. Key Study Features
  5. Eligibility Criteria
  6. DCCT Randomization
  7. Baseline Characteristics
  8. Conventional Therapy
  9. Intensive Therapy Goals
  10. Intensive Therapy Methods
  11. Glycemic Control
  12. Intensive Therapy Improved Glycemic Control
  13. Glycemic Control: Intensive and Conventional Therapy
  14. Measures of Success as a Clinical Trial
  15. Retinopathy
  16. Retinopathy Measures
  17. Level of Retinopathy
  18. Sustained 3-Step Change: Primary Cohort
  19. Sustained 3-Step Change: Secondary Cohort
  20. Photocoagulation: Secondary Cohort
  21. Macular Edema: Secondary Cohort
  22. Retinopathy Risk Reduction: Primary Cohort
  23. Retinopathy Risk Reduction: Secondary Cohort
  24. Subgroup Analysis for Retinopathy
  25. Rate of Retinopathy Progression
  26. Nephropathy
  27. Measures of Nephropathy
  28. Microalbuminuria Greater Than Or Equal To 40mg/24 Hours: Combined Cohort
  29. Albuminuria Greater Than Or Equal To 300mg/24 Hours: Combined Cohort
  30. Risk Reduction With Intensive Therapy
  31. Neuropathy
  32. Neuropathy Measures
  33. Definition of Clinical Neuropathy
  34. Neuropathy: 5 Year Prevalence in Those Without Baseline Neuropathy
  35. Summary
  36. Macrovascular Disease
  37. Incidence of Cardiac Risk Factors: Combined Cohort
  38. Hypertension: Combined Cohort
  39. LDL Cholesterol >160 mg/dL: Combined Cohort
  40. Macrovascular Events
  41. Major Macrovascular Events: Combined Cohort
  42. Major Macrovascular Events: Combined Cohort, Continued
  43. Adverse Events
  44. Summary
  45. Mortality
  46. Adverse Effects of Therapy
  47. Body Weight >120% of Ideal: Combined Cohort
  48. Adverse Events
  49. Severe Hypoglycemia
  50. Severe Hypoglycemia: Combined Cohort
  51. Risk Factors for Severe Hypoglycemia
  52. Risk of Hypoglycemia
  53. Neurobehavioral, Psychological, and Quality of Life Assessments
  54. Recommendations
  55. Risk: Benefit Ratio May Be Less Favorable
  

dot

Diabetes Home | Diabetes A to Z | Introduction | Treatments | Complications | Statistics | Clinical Trials | NDEP | Awareness and Prevention | Additional Resources | Order Publications | About Us | Información en Español

Contact Us | Health Information

The NDIC is a service of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

National Diabetes Information Clearinghouse
1 Information Way
Bethesda, MD 20892–3560
Phone: 1–800–860–8747
Fax: 703–738–4929
Email: ndic@info.niddk.nih.gov
Privacy | Disclaimer | Accessibility
H H S logo - link to U. S. Department of Health and Human Services
NIH logo - link to the National Institute of Health
NIDDK logo - link to the National Institute of Diabetes and Digestive and Kidney Diseases